As ongoing trials evaluate tebentafusp in cutaneous melanoma patients following disease progression on anti-PD1 therapy (NCT05549297), it will be critical to determine whether there is a threshold for gp100 expression below which patients are unlikely to respond. Here, PMEL is linked to cutaneous melanoma.